Changing epidemiology of post-MI HF? In Scotland, year 2015 vs 1991-92 ⬇️46% in mortality ⬇️53% in HF hosp in the year after first acute MI BUT ⬆️2.5 fold risk of death after HF hosp Find this & MORE @ EJHF onlinelibrary.wiley.com/doi/10.1002/ej…

Subcutaneous furosemide for patients with heart failure. Promising results of 2 phase I trials. Published this week and featured in today's episode of ESC TV Today. esc365.escardio.org/event/1137 #furosemide #SQfurosemide academic.oup.com/ehjcvp/article…

Enroute to Philadelphia for #AHA23 Will be presenting some new data from DAPA-HF on Monday at 10:30AM - Interleukin-6 in Patients With HFrEF and the Effect of Dapagliflozin (Poster Board 2229)

Fantastic few days at CVCT - CardioVascular Clinical Trialists. Great talks on recent and upcoming trials with some thought provoking discussions and an opportunity to catch up with friends and colleagues. Thanks to Faiez ZANNAD for the opportunity and support through the Young Clinical Trialist Fellowship

Sacubitril/valsartan and Alzheimer's disease biomarkers. Great collaboration with Wagner S. Brum demonstrating an important drug-test interaction with a commonly used AD blood test (Aβ42/Aβ40). Also reassuring results in other biomarkers of neurodegeneration jamanetwork.com/journals/jaman…

To become the future of the clinical trials, apply here : globalcvctforum.com/future-trialis… #CardioTwitter #Diversity #clinicalresearch

Honored, humbled and very excited to be selected as candidate for position of president-elect for the #HFA board elections! To all members, please don’t forget to vote for these fantastic people! escardio.org/Sub-specialty-… Here are my top six priorities....together we can make it

EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with LVSD after an acute MI. doi.org/10.1002/ehf2.1… Jaclyn Carberry Mark Petrie Colin Berry Kieran Docherty University of Glasgow Heart Failure Research Group UofG SCMH BHF CoRE Glasgow #HF #MI #SGLT2i

Great to see the design paper of our mechanistic remodelling trial of SGLT2i following acute MI published - final study visits in the next few weeks and hopefully results will be ready to present later this year!

New review in #JACCHF by Kieran Docherty on the treatment and prevention of HF following AMI. * Review of current evidence and guideline recommendations * Discussion of ongoing research * Proposal to identify highest risk pts to guide tx 🔥Don't miss!! jacc.org/doi/10.1016/j.…

As #ESCCongress kicks off, I am proud to share this review article on Digital Tools in Heart Failure, where we tried to cover all aspects of this promising field Open access The Lancet Digital Health 😊 sciencedirect.com/science/articl… @DrJasper1 Kieran Docherty C. Michael Gibson MD Carolyn Lam

Simultaneous Publication w/ #ESCCongress 2024 from University of Glasgow Heart Failure Research Group & Kieran Docherty et al: Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients with Heart Failure: An Analysis of the DETERMINE Trials ahajournals.org/doi/10.1161/CI… #AHAJournals

Delighted to present these data today from the DETERMINE trials at the #ESCCongress The first evidence of a beneficial effect of a HF therapy on accelerometer-based measures of physical activity. A promising new outcome measure for HF trials.

An age-old hemodynamics debate: pressure vs volume. Pressure-guided RPM are available, but what about volume? 🚨FUTURE-HF2 trial: Out Now in Journal of Cardiac Failure! Safety & feasibility of the FIRE1 implantable IVC sensor from #HFSA2024 🔗 bit.ly/3TOMUr3

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in HFmrEF/HFpEF: a Prespecified Analysis of The FINEARTS-HF Trial Now online Circulation after presentation at #HFSA2024 Consistent benefit of finerenone regardless of LVEF ahajournals.org/doi/10.1161/CI…

EMPRESS-MI now published. No effect of empagliflozin on ventricular remodelling in patients with LVEF ≤45% following acute MI. However...very few patients had progressive adverse remodelling. The challenge is identifying patients at risk of adverse remodelling in the modern era.

#PREVENTHF launching Mar '25 New large first-of-its-kind #CKM trial focused on *prevention* of HF n=11,300 pts w T2D, ASCVD, HTN (but w/o HF) Randomization: ASi (baxdrostat) + SGLT2i (dapagliflozin) vs SGLT2i alone PEP: new diagnosis of HF or CV death clinicaltrials.gov/study/NCT06677…

📣Can wearable accelerometers predict HF outcomes? Original research with a subgroup of DETERMINE trial patients showed: ⬇️Physical activity assessed by accelerometer🏃🏾‍♂️ --> ⬇️KCCQ, ⬇️ 6MWD, ⬆️ NT-proBNP #Wearables #HFoutcomes 🔗bit.ly/4cAnB4f

Dr Taylor-Sweet presents #TARTANHF trial design 🏴󠁧󠁢󠁳󠁣󠁴󠁿multicentre RCT ❓does natriuretic peptide-based screening detect undiagnosed #heartfailure in high-risk diabetes patients vs routine care 🧑‍🤝‍🧑700 participants 🗓️results in 2026 #HeartFailure2025 Kieran Docherty Mark Petrie

Elevated IL-6 & hs-CRP levels = higher risk of worsening HF or #cvDeath in #HFrEF patients, based on DAPA-HF study. ✅ However, #dapagliflozin reduced outcomes regardless of baseline inflammation 📎jacc.org/doi/10.1016/j.… #JACCHF #HeartFailure scottdavidsolomon